Saama Technologies raises USD 40 Million to bolster AI
Saama Technologies has got a hefty investment of USD 40million to accelerate its Artificial Intelligence and bolster its use in the branch of Life Sciences. This will help the California based data analytics company to innovate, curate and accelerate the clinical trials and deliver credible data.
FDA approves the first-ever drug for PPD
The U.S. FDA has approved the first-ever drug for treating postpartum depression (PPD). The drug Zulresso (brexanolone) will be injected intravenously (IV) and will be provided through a special program called the Zulresso REMS Program, which requires the drug to be administered by a health care provider in a certified health care facility.
Motif Bio issues share worth USD 3.55 million
Motif Bio, a clinical-stage biopharmaceutical company has raised USD 3.55 million as IPO via the issue of 45,000,000 ordinary shares at 6p per Placing Share. The net proceeds will be used for iclaprim for treating acute bacterial skin and skin structure infections.
Novartis multiple sclerosis drug gets approval
The FDA has approved a drug Mayzent to treat Multiple sclerosis– the first new one in the last fifteen years. The Swiss drugmaker Novartis has claimed that drug is the only candidate in the market which has proved itself to be the most effective one in treating secondary progressive MS.
Bammer Bio acquires Thermo Fisher
US-based Brammer Bio has been acquired by the Thermo Fisher- a life sciences group. The duo plans to revolutionize and to gain momentum in the use of Gene therapy to deliver breakthrough drugs. The acquisition will enable Thermo Fisher to gain an edge in serving biotech customers and Brammer Bio to evolve its gene therapies models.